ClinicalTrials.gg
RecruitingNCT04807673KEYSTONE-002Updated Jun 1, 2022

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

A Phase 3 interventional study of Pembrolizumab and Paclitaxel in Esophageal Squamous Cell Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 3, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma — 5 open to participants now, 6 under way, 2 of them phase 3. pembrolizumab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
2nd of 17
342 · median 50
Started
2021
with 1 other
Phase 3
2 of 17
1 open now
Registered
9th of 17
by date
Lead sponsor
2 of 17
Tianjin Medical University Cancer Institute and Hospital

Among the 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2021, is one of 2 in phase 3, and was the 9th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

5 of the 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as adjuvant therapy, compared with neoadjuvant chemoradiotherapy and surgery for locally advanced ESCC in multicenter.

Read the detailed description

Preoperative chemoradiotherapy with radical surgery is the recommended treatment for locally advanced esophageal squamous cell carcinoma (ESCC) in the NCCN guidelines. But many patients refused or abandon radiotherapy because of the intolerable adverse effects. The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as adjuvant therapy, compared with neoadjuvant chemoradiotherapy and surgery for locally advanced ESCC in multicenter. The primary study hypothesis is that Event Free Survival (EFS) is superior with pembrolizumab plus neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy in participants with ESCC.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • esophageal squamous cell carcinoma
  • Immunotherapy
  • neoadjuvant therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed esophageal squamous cell carcinoma;
  2. R0 resectable thoracic esophageal cancer, cT1-3N1-2M0, cT2-3N0M0 (AJCC V8 TNM classification);
  3. No suspicious lymph nodes on the clavicle;
  4. Have a performance status of 0 or 1 on the Performance Scale;
  5. Age 18-75 years old, both men and women;
  6. Be willing and able to provide written /assent for the trial;
  7. Demonstrate adequate organ function ;
  8. Female subject of should have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;
  9. Be willing to provide tissue, blood, and urine samples. Tissue should be from a newly obtained core or excisional of a tumor lesion through repeated biopsies. Newly-obtained is defined as a specimen obtained up to 4 weeks (28 days) before initiation of treatment on Day 1.
  10. Have not received systemic or local treatment for esophageal cancer in the past.

Exclusion criteria

Exclusion Criteria:

  1. Ineligibility or for esophagectomy;
  2. Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal cancer
  3. Active disease or history of autoimmune disease;
  4. Requiring systemic treatment with either or other medications;
  5. Subjects with a history of symptomatic interstitial lung disease;
  6. History of allergy to study drug components;
  7. Women must not be pregnant or breast-feeding;
  8. Patient has received prior chemotherapy, radiotherapy, target therapy ,and immune therapy for this or any other past malignancy;
  9. Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
342 participants (estimated)

Study arms

  • Experimental
    Pembrolizumab+ Paclitaxel+Cisplatin+ Surgery+Pembrolizumab (228)

    Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W), paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and cisplatin 80 mg/m\^2 IV on Day 2 Q3W, a total of three cycles. All treatments will be beginning on Day 1 of each 3-week dosing cycle. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. After surgery, pembrolizumab 200 mg IV on Day 1 Q3W lasting one year. Surgery: McKeown esophagectomy

    Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Cisplatin

  • Experimental
    neoadjuvant chemoradiotherapy+ Surgery (114)

    neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week. Surgery should be done within 4-6 weeks after the last neoadjuvant treatment. Surgery: McKeown esophagectomy

    Radiation: neoadjuvant chemoradiotherapy

Interventions

  • BiologicalPembrolizumab

    Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles. Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.

    Also known as: Keytruda

  • Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.

  • Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.

  • Radiationneoadjuvant chemoradiotherapy

    neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week

06

What researchers measure

Primary outcomes

  1. Event Free Survival (EFS)

    EFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigator, or recurrence, or metastasis, or death due to any cause, whichever occurs first. For this analysis, EFS will be assessed in participants with ESCC.

    Time frame: Up to approximately 2.5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: 3 and 5 years

  2. Disease Free Survival (DFS)

    Percentage of Participants With DFS, as Assessed by RECIST 1.1. DFS is defined as the time from randomization to the first documented disease progression of local recurrence or distant metastasis or death due to any cause.

    Time frame: 3 and 5 years

  3. Major pathologic response (MPR)

    MPR is defined as viable tumor comprised ≤ 10% of resected tumor specimens.

    Time frame: 1 month after resection

  4. Objective response rate (ORR)

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by investigator. For this analysis, ORR will be assessed in all participants.

    Time frame: 1 month after resection

  5. Pathologic Complete Response (PCR)

    PCR is defined as pT0N0M0

    Time frame: 1 month after resection

  6. assessment in perioperation

    R0 resection rate, Time of operation, Quantity of bleeding, Thoracic Drainage, Days of Hospitalization, Rate of Operative Complication, Mortality of perioperation

    Time frame: perioperative period

  7. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    All participants with treatment-related adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Event,Version 4.0(CTC AE4.0).

    Time frame: up to 16 months

  8. Quality of life differences (EORTC QLQ-C30)

    The quality of life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire. Patients will be invited to finish the questionnaire at the first day of randomization, before surgery and after surgery (3m, 6m, 12m and 24 months).

    Time frame: 2.5 years

  9. Quality of life differences (EORTC QLQ-OES18)

    The quality of life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-OES18) questionnaire. Patients will be invited to finish the questionnaire at the first day of randomization, before surgery and after surgery (3m, 6m, 12m and 24 months).

    Time frame: 2.5 years

07

Study locations

1 of 1 sites recruiting
  • Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
    Recruiting
    • Hongjing Jiang, MD,PhD · Contactjianghongjing@tmu.edu.cn · 18622221069
    • Xiaobin Shang, MD,PhD · Contactshangxiaobin@tmu.edu.cn · 18622221071
    • Hongjing Jiang, MD,PhD · Principal investigator
    • Yin Li, MD,PhD · Principal investigator
    • Zhigang Li, MD,PhD · Sub investigator
    • Hecheng Li, MD,PhD · Sub investigator
    • Peng Zhang, MD,PhD · Sub investigator
    • Ziqiang Tian, MD,PhD · Sub investigator
    • Jianqun Ma, MD,PhD · Sub investigator
    • Yegang MA, MD,PhD · Sub investigator
    • Shiping Guo, MD,PhD · Sub investigator
    • Haibo Cai, MD · Sub investigator
    • Hengxiao Lu, MD · Sub investigator
    • Lin Zhang, MD,PhD · Sub investigator
08

References and documents

Publications

  • Shang X, Zhang W, Zhao G, Liang F, Zhang C, Yue J, Duan X, Ma Z, Chen C, Pang Q, Zhang W, Liu L, Ren X, Meng B, Zhang P, Ma Y, Zhang L, Li H, Kang X, Li Y, Jiang H. Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). Front Oncol. 2022 Mar 31;12:831345. doi: 10.3389/fonc.2022.831345. eCollection 2022. PubMed 35433421 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2023, 24 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 19, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Dec 31, 2023
CompletionEst.
May 2028
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04807673
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Ruijin Hospital, Hebei Medical University Fourth Hospital, Harbin Medical University, Liaoning Cancer Hospital & Institute, Shanxi Province Cancer Hospital, Jining First People's Hospital, Weifang People's Hospital, Tianjin Medical University General Hospital, Shandong Provincial Hospital
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Dec 1, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
May 2028 (estimated)
Last update
Jun 1, 2022

Study contacts

Hongjing Jiang, MD,PhD
Contact
jianghongjing@tmu.edu.cn
18622221069
Xiaobin Shang, MD,PhD
Contact
shangxiaobin@tmu.edu.cn
18622221071

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Paclitaxel · Cisplatin

Start the discussion